Hyperglycemia-Stimulated Myelopoiesis Causes Impaired Regression of Atherosclerosis in Type 1 Diabetes  by Brownlee, Michael
Cell Metabolism
PreviewsHyperglycemia-Stimulated Myelopoiesis
Causes Impaired Regression
of Atherosclerosis in Type 1 DiabetesMichael Brownlee1,*
1Diabetes Research Center and Departments of Internal Medicine and Pathology, Albert Einstein College of Medicine,
1300 Morris Park Avenue, Bronx, NY 10461, USA
*Correspondence: michael.brownlee@einstein.yu.edu
http://dx.doi.org/10.1016/j.cmet.2013.04.015
People with type 1 diabetes (T1D) have a high risk of early morbidity and mortality from coronary artery
disease. A study in this issue ofCell Metabolism (Nagareddy et al., 2013) now identifies amechanism causing
impaired regression of atherosclerosis in T1D.Coronary artery disease (CAD) is the
leading cause of death in type 1 diabetes
(T1D) (Schauer et al., 2011). This is sur-
prising, because the major CAD risk
factors that characterize type 2 diabetes
are not present in T1D. While better regu-
lation of hyperglycemia over the past 20
years has reduced the incidence of micro-
vascular damage in the kidney, CAD rates
in T1D patients have not declined, sug-
gesting that hyperglycemia and resultant
kidney dysfunction may not be critical
elements in the pathogenesis of diabetic
macrovascular complications. Unfortu-
nately, very little is known about how
T1D accelerates coronary atheroscle-
rosis, hampering the discovery of new
therapeutic targets.
In this issue of Cell Metabolism, Nagar-
eddy et al. (2013) advance our under-
standing of coronary artery disease in
T1D. They show how hyperglycemia
increases bone marrow production
of neutrophils and monocytes, causing
increased entry of these cells into early
atherosclerotic lesions. Reduction of
hyperglycemia by blocking renal glucose
reabsorption with a sodium-glucose
cotransporter 2 (SGLT2) inhibitor reduces
monocytosis and monocyte entry into
atherosclerotic lesions, thereby pro-
moting lesion regression. These findings
suggest new directions for future re-
search and drug development.
Atherosclerosis lesions begin with the
deposition of cholesterol-rich lipoproteins
in the artery wall, followed by the entry of
inflammatory leukocytes into lesions.
When there is an imbalance between sys-
temic lipid metabolism, transport of lipid
into and out of the lesion, and cellular
and innate immune system dysfunction,lesions progress rather than resolve. Early
lesions are characterized by infiltration of
neutrophils and lipid-filled monocyte-
derived macrophages. During lesion pro-
gression,bothsmoothmusclecell prolifer-
ation and alteredmatrix production occur.
Advanced lesions accumulate a variety of
inflammatory cell types and a necrotic
core containing dead macrophage foam
cells, prothrombotic molecules, and
matrix proteases. A large necrotic core
predisposes to release of thrombogenic
material due toproteaseerosionor rupture
of the plaque (Weber and Noels, 2011).
A study in people with T1D showing an
association between increased circu-
lating leukocyte number and CAD severity
(Orchard et al., 2003) and another in
hyperlipidemic mice showing that in-
creased circulating neutrophils promoted
early lesion formation (Drechsler et al.,
2010) led Nagareddy et al. to investigate
the mechanisms responsible for neutro-
philia and monocytosis in T1D diabetes
and to determine whether this was
responsible for the impaired regression
of early atherosclerotic lesions. Nagar-
eddy et al. found that hyperglycemia
increased reactive oxygen species pro-
duction in bone marrow neutrophils, stim-
ulating production and secretion of the
damage-associated molecular pattern
molecules (DAMPs) S100A8 and S100A9
in bone marrow and plasma (Nagareddy
et al., 2013). S100A8/S100A9 binding to
the pattern recognition receptor RAGE
(receptor for advanced glycation end-
products) on the surface of bone marrow
macrophages was found to stimulate
secretion of GM-CSF, while S100A8/
S100A9 binding to RAGE on bonemarrow
common myeloid progenitor cells (CMP)Cell Metaboliswas shown to stimulate secretion of
M-CSF. M-CSF stimulates proliferation
of CMPs and, in conjunction with
GM-CSF, also stimulates proliferation of
granulocyte-monocyte progenitor cells
(GMPs). The proliferating GMPs differen-
tiate in the bone marrow to form mono-
cytes and neutrophils, which are then
released into the circulation (Figure 1).
With the mechanism underlying hyper-
glycemia-induced neutrophilia andmono-
cytosis established, Nagareddy et al. next
investigated whether this increase inmye-
lopoiesis was responsible for impaired
regression of early atherosclerotic lesions
in T1D (Nagareddy et al., 2013). Defects in
lesion regression can result from changes
in monocyte egress and/or from changes
in macrophage entry. To assess the
effects of monocyte egress versus entry
on macrophage burden in diabetic mice,
two different models were used. Egress
rates from regressing lesions in untreated
and SGLT2 inhibitor-treated T1D mice
were similar. In contrast, the number of
L-selectin and MCP-1 receptor-bearing
monocytes (Ly6-Chi) entering regressing
lesions from T1D mice was much greater
than in regressing lesions from SGLT2
inhibitor-treated diabetics and nondia-
betics. These data demonstrate that hy-
perglycemia-induced increases in bone
marrow production and circulating num-
ber of neutrophils and monocytes impair
regression of early atherosclerosis lesions
in T1D mice by increasing macrophage
entry. Reduction of hyperglycemia by
blocking renal glucose reabsorption with
a SGLT2 inhibitor reduced monocytosis
and monocyte entry into atherosclerotic
lesions and thereby promoted lesion
regression. Finally, Nagareddy et al.m 17, May 7, 2013 ª2013 Elsevier Inc. 631
Figure 1. Hyperglycemia-Induced Stimulation of Myelopoiesis Impairs the Regression of Atherosclerosis in Type 1 Diabetes
Hyperglycemia increases bonemarrow (BM) neutrophil secretion of the S100A8/S100A9 heterodimer through anROS-mediatedmechanism. In the BM, S100A8/
S100A9 binds to the pattern recognition receptor RAGE on macrophages and CMPs. S100A8/S100A9 binding stimulates macrophages to secrete GM-CSF and
stimulates CMPs to secrete M-CSF. M-CSF stimulates CMP proliferation in an autocrine fashion. M-CSF and GM-CSF stimulate GMP proliferation. The prolif-
erating GMPs differentiate in the BM to form neutrophils and monocytes, which are then released into the circulation. Increases in bone marrow production and
circulating number of neutrophils and monocytes impair regression of early atherosclerosis lesions by increasing macrophage entry into the lesion.
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increased plasma S100A8/S100A9 levels
and increased leukocyte counts are
associated with coronary artery disease
(Nagareddy et al., 2013).
This pioneering study provides the con-
ceptual basis for addressing several
follow-up questions. One important ques-
tion to address with these models is the
role of insulin resistance in impaired lesion
regression. In T1D patients, the extent of
insulin resistance, an independent risk
factor for CAD in nondiabetics, predicts
the extent of coronary artery calcification
(Schauer et al., 2011). The related ques-
tion of differentiating the effect of high
peripheral insulin levels caused by subcu-
taneous insulin injection in T1D from the
effect of hyperglycemia could also be
answered using these models.
Another important unanswered ques-
tion concerns the mechanisms involved632 Cell Metabolism 17, May 7, 2013 ª2013in the phenomenon of metabolic memory
in T1D (Giacco and Brownlee, 2010). The
Diabetes Control and Complications Trial
(DCCT) showed that intensive therapy
for 6 years significantly reduced develop-
ment of microvascular complications in
type 1 diabetes. Intensive therapy also
lowered HbA1c values compared to the
nonintensive treatment group. However,
during the subsequent 11 year follow-up
study of these patients, the two groups
had identical HbA1c values. Surprisingly,
intensive treatment during the 6 year
DCCT reduced the risk of any CVD event
by 42% and the risk of nonfatal myo-
cardial infarction, stroke, or death from
CVD by 57% over the subsequent 11
year period (Nathan et al., 2005). If meta-
bolic memory occurs in this mouse model
of lesion regression, much could be
learned about the underlying molecular
mechanisms.Elsevier Inc.Finally, the critical problem for people
with T1D is their high risk of increased
mortality from premature CAD (Orchard
et al., 2006; Schauer et al., 2011). It seems
likely that they, like people with T2D and
CAD, have impaired regression of athero-
sclerosis despite lowering of plasma lipid
levels (Hiro et al., 2010). Using the T1D
murine models described, it should be
possible to test several candidate thera-
peutic approaches. Since impaired lesion
regression was shown to depend on
hyperglycemia-induced ROS in bone
marrow neutrophils, ROS prevention
would be one reasonable candidate,
particularly because inhibition of hyper-
glycemia-induced ROS by transgenic
overexpression of superoxide dismutase
isoforms prevents experimental diabetic
retinopathy, nephropathy, neuropathy,
and cardiomyopathy (Giacco and Brown-
lee, 2010). Other promising candidate
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Previewstargets for therapy have been reviewed
recently in these pages by Rask-Madsen
and King (2013).
The exciting findings of Nagareddy
et al. mark amajor breakthrough in under-
standing why people with T1D develop
accelerated CAD. This advance also
provides a model that could be used to
address many important unanswered
questions in the field.
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Mechanistic target of rapamycin complex 1 (mTORC1) regulates growth and metabolism by integrating
signals from the cellular environment. Ben-Sahra et al. (2013) and Robitaille et al. (2013) demonstrate a
role for mTORC1 in nucleotide production via S6K1 phosphorylation of CAD, which catalyzes the initial steps
of de novo pyrimidine biosynthesis.Cell growth is an intricately tuned process
involving the coordinated control of
anabolic and catabolic processes. The
mechanistic target of rapamycin complex
1 (mTORC1) lies at the center of this coor-
dination by controlling the production of
macromolecules such as lipids, proteins,
and nucleic acids. Under conditions of
nutrient sufficiency,mTORC1upregulates
protein synthesis by promoting translation
and ribosome biogenesis both directly
and through the 40S ribosomal S6 kinases
(S6K1 and S6K2) and the eukaryotic initia-
tion factor 4E (eIF4E)-binding proteins
(4EBPs) (Ma and Blenis, 2009; Laplante
and Sabatini, 2012). mTORC1 also con-
trols the SREBP1/2 transcription factors,
which drive the expression of numerous
genes involved in lipid/sterol biosynthesis
(Du¨vel et al., 2010). In addition, mTORC1
is believed to control nucleotide syn-thesis, but themechanisms for this regula-
tion have been unclear. Two studies
recently published in Science by Ben-
Sahra et al., (2013) and Robitaille et al.
(2013) demonstrate how mTORC1 pro-
motes de novo pyrimidine synthesis
through posttranslational regulation of
the multifunctional enzyme CAD (carba-
moyl-phosphate synthetase 2, aspartate
transcarbamoylase, dihydroorotase).
Using unbiasedmetabolomics profiling,
Ben-Sahra et al. compared mouse em-
bryonic fibroblasts (MEFs) lacking the
tuberous sclerosis complex 2 (Tsc2) gene
to MEFs with intact Tsc2. Tsc2 is a nega-
tive regulator of mTORC1, and Tsc2 loss
leads to mTORC1 hyperactivation. Of the
20 metabolites that were significantly
increased in the Tsc2/ cells, only
one metabolite, N-carbamoyl-L-aspar-
tate, was decreased in response to bothacute and longer-term treatment with
the mTORC1 inhibitor rapamycin. As
N-carbamoyl-L-aspartate is generated in
the first committed step of de novo pyrim-
idine biosynthesis, the authors focused on
CAD, which catalyzes the first three steps
in this pathway; the E1/E2 enzymatic
activities of CAD catalyze the formation
of N-carbamoyl-L-aspartate, which is
subsequently catalyzed into dihydrooro-
tate by E3 enzymatic activity (Figure 1).
In a different approach, Robitaille et al.
employed phosphoproteomics in MEFs
lacking Raptor, an essential component
of mTORC1, to identify mTORC1 targets.
They identified possible targets involved
in RNA metabolism and DNA replication,
leading to their investigation of CAD.
Both groups identified S1859 on CAD
as an mTORC1-regulated phosphoryla-
tion site via MS/MS. Consistent with them 17, May 7, 2013 ª2013 Elsevier Inc. 633
